A Phase II Study of ERK Inhibition by Ulixertinib (BVD-523) in Metastatic Uveal Melanoma.

ABSTRACT:

Purpose

Uveal melanoma is a rare and aggressive subset of melanoma that is minimally responsive to traditional therapies. Greater than 80% of uveal melanomas have a mutation in GNAQ or GNA11 which lead to downstream signaling through the MAPK pathway. Ulixertinib (BVD-523) is a potent and reversible small-molecule ATP-competitive inhibitor of both ERK1 and ERK2 protein kinases.

Materials and methods

We performed a phase II study to determine the efficacy and safety of BVD-523 in patients with metastatic uveal melanoma. This was conducted as a Simon two-stage design with a sample size of 25 patients and an initial evaluation of efficacy after 13 patients.

Results

From April 2018 to April 2019, 13 patients were enrolled. Patients were predominantly female (69%) with a m

SUBMITTER: Buchbinder EI 

PROVIDER: S-EPMC11107576 | biostudies-literature | 2024 May

REPOSITORIES: biostudies-literature